Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Study of expanded dosing of sodium oxybate drug combination in adults with narcolepsy or idiopathic hypersomnia

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on two rare sleep disorders, Narcolepsy and Idiopathic Hypersomnia. Both conditions cause excessive daytime sleepiness, meaning people feel very sleepy during normal waking hours, and can affect daily activities. The medication being tested is Xywav, a product that contains the active ingredient sodium oxybate along with related compounds. The purpose of the study is to evaluate the efficacy and safety of expanded dosing regimens of Xywav in adults with these disorders.

Participants first receive a stable dose of the medication for several weeks to allow the body to adjust. After this period, they are randomly assigned to continue receiving the study medication or to receive a placebo, a substance that looks the same but does not contain the active drug. Over the next few months, researchers track changes in daytime sleepiness using tools such as the Epworth Sleepiness Scale, a questionnaire where people rate how likely they are to fall asleep in different situations. They also monitor other symptoms, including sudden loss of muscle tone called cataplexy, and collect diary information about sleep patterns. Safety is checked by recording any side effects and routine health measurements.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Start of Study Medication

    After joining the study, you are randomly assigned to receive either Xywav (the test medication) or a matching placebo. The assignment is unknown to you and the study staff.

    If you receive Xywav, the medication is an oral solution containing sodium oxybate, calcium oxybate, magnesium oxybate, and potassium oxybate, taken at a dose of 12 g per day as directed by the study team.

  2. Step 2

    Stable Dose Period (SDP)

    You continue taking the assigned medication at the same dose each day. This period is called the Stable Dose Period and lasts until the dose is considered stable, typically after several weeks of consistent use.

    During this time you complete questionnaires that measure daytime sleepiness, such as the Epworth Sleepiness Scale, and keep a sleep diary that records total sleep time, sleep latency, awakenings, and sleep quality.

  3. Step 3

    Assessments During SDP

    Study visits are scheduled regularly to collect safety information, including vital signs, laboratory tests, and an electrocardiogram (ECG).

    You also answer the Clinical Global Impression of Change and Patient Global Impression of Change questions, which ask how your symptoms have changed since the start of the study.

  4. Step 4

    Transition to Double‑Blind Randomized‑Withdrawal Phase (DBRWP)

    After the Stable Dose Period, the study enters the Double‑Blind Randomized‑Withdrawal Phase. The study remains blind, meaning you continue to receive either the same medication or a switch to placebo without knowing which you have.

  5. Step 5

    Medication Administration During DBRWP

    You keep taking the oral solution each day at the same dose of 12 g, whether it is Xywav or the placebo, according to the randomization schedule.

  6. Step 6

    Ongoing Safety and Efficacy Monitoring

    Regular visits continue throughout the withdrawal phase. At each visit the study team checks for any adverse events, measures vital signs, repeats laboratory tests, and records ECG results.

    You again complete the Epworth Sleepiness Scale, the Idiopathic Hypersomnia Severity Scale (if applicable), the Narcolepsy Severity Scale, and daily sleep and sleepiness diaries to track any changes.

  7. Step 7

    End‑of‑Study Assessments

    At the conclusion of the double‑blind randomized‑withdrawal phase, a final set of questionnaires and clinical evaluations is performed to determine how your daytime sleepiness and other symptoms have changed.

    The study team reviews all safety data collected during the trial before closing your participation.

Who can join the trial?

14 criteria

  • You must be between 18 and 75 years old when you sign the consent form.
  • If you are taking medicines that prevent cataplexy (sudden loss of muscle tone) and those medicines are not oxybate, you must agree to slowly stop them under your doctor’s guidance and stay off them for the whole study, unless you need them for another health reason.
  • If you use nicotine replacement therapy (such as patches, gum, or lozenges), you must have taken the same dose for at least one month before screening and you must not plan to change the dose during the study.
  • Female participants must not be pregnant or breastfeeding. You must either use a reliable form of birth control (with less than 1% chance of failure per year) or meet other specific study requirements, have a negative pregnancy test, and agree not to donate eggs while in the study.
  • You must be able to give a signed informed consent and agree to follow all study rules and restrictions.
  • You must be willing and able to follow the study schedule, complete all required assessments, and take the medication exactly as instructed.
  • You must have a doctor‑confirmed diagnosis of either idiopathic hypersomnia (excessive sleepiness without a known cause) or narcolepsy (type 1 or type 2) that meets the official diagnostic guidelines (ICSD‑3 or DSM‑5).
  • If you have narcolepsy type 1, you must have experienced at least 14 cataplexy attacks in a typical two‑week period before starting any treatment.
  • If you have idiopathic hypersomnia, you must normally sleep at least 7 hours each night based on your history before treatment.
  • If you are not currently taking oxybate, you must have noticeable daytime sleepiness with an Epworth Sleepiness Scale (ESS) score greater than 11. (The ESS is a questionnaire that asks how likely you are to fall asleep in everyday situations; higher scores indicate more sleepiness.)
  • If you are currently taking oxybate, your doctor must have documented that it has improved your daytime sleepiness.
  • If you are currently taking oxybate, you must have been on a stable nightly dose between 3 g and 9 g for at least two months before screening.
  • If you stopped taking oxybate in the past, you must have been off the medication for at least two weeks before screening and you must not have stopped because of side effects, safety concerns, or lack of benefit.
  • If you are using alerting agents (such as traditional stimulants like amphetamines or methylphenidate, or wake‑promoting agents like modafinil, pitolisant, or solriamfetol), you must have taken the same dose for at least one month before screening and have no plans to change the dose during the study. Medications called OX2R agonists are not allowed.

Who cannot join the trial?

24 criteria

  • Having another sleep problem that is not treated well enough, such as sleep apnea (breathing stops many times at night), parasomnias (unusual behaviors during sleep), circadian‑rhythm disorders (body clock out of sync), or restless‑legs syndrome (uncontrollable urge to move the legs), will keep you from joining.
  • Having a severe allergy or a strong allergic reaction (like asthma attacks or hives) to Xyrem, Xywav, GHB, or any of the ingredients in these medicines means you cannot take part.
  • If you have a history of substance abuse (using drugs or alcohol in a harmful way) or a positive drug test for illegal drugs or alcohol, you are not eligible.
  • Using any of the following within one month before screening, or planning to use them during the study, will exclude you:
    • Alcohol or sleep‑making medicines such as benzodiazepines, barbiturates, or other “sleep pills.”
    • Medications that interact with Xywav, like valproic acid or divalproex.
    • Drugs that cause strong drowsiness, such as certain sleep‑aid medicines (e.g., suvorexant, lemborexant, daridorexant), melatonin‑type medicines (e.g., ramelteon, tasimifene), antipsychotics, some anti‑seizure medicines, and some antidepressants that make you very sleepy (unless you have been on a stable dose for at least six months for another condition).
    • Opioid pain medicines or any general anesthetic.
    • Other sedating products like antihistamines that make you sleepy or natural sleep aids. These must be stopped at least two weeks before joining.
    • Taking an OX2R agonist (a type of experimental sleep medicine) within one month before screening will exclude you.
    • Having a tobacco‑use disorder or regularly vaping in a way that wakes you up at night prevents participation.
    • Drinking more than four caffeinated drinks a day (about 400 mg of caffeine) will keep you from the study.
    • Having taken any other experimental drug within the past 30 days (or five drug half‑lives, whichever is longer) makes you ineligible.
    • Having lab test results that are far outside normal limits (for example, liver enzymes more than three times the upper limit) or a heart test (ECG) that shows significant problems will exclude you.
    • If you were once eligible for this study but stopped the medication early or were withdrawn, you cannot re‑enter.
    • Working a job that requires night shifts or irregular work hours will prevent participation.
    • Having a medical condition called succinic semi‑aldehyde dehydrogenase deficiency excludes you.
    • Planning to travel across more than three time zones while the study is ongoing will make you ineligible.
    • Having uncontrolled hypothyroidism (an under‑active thyroid that is not properly treated) will keep you from joining.
    • Having a current seizure disorder (a condition that causes seizures) excludes you.
    • Having a head injury with loss of consciousness in the past five years, or an older injury that still causes problems, will disqualify you.
    • Having bipolar disorder, schizophrenia, or any other psychotic disorder according to standard diagnostic criteria will prevent participation.
    • Having any unstable or serious medical, behavioral, or psychiatric condition (such as chronic pain that disrupts sleep, active thoughts of suicide, a major depressive episode in the past year, another neurological disease, or recent major surgery) that could affect your safety or the study results makes you ineligible.
    • Having any other significant disease or condition that the investigator believes could put you, other participants, or study staff at risk, or could affect the study’s results, will exclude you.
    • Having any condition that, in the investigator’s opinion, would make it unsafe to take higher doses of the study medication (more than 6 g once nightly up to 7.5 g, or a total of more than 9 g to 12 g split into two nightly doses) will keep you from participating.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

JZP258 is an oral liquid medication that contains a combination of four salts of oxybate (sodium, calcium, magnesium, and potassium). It is taken by mouth, usually at night, and is designed to improve the quality of nighttime sleep. By helping the brain get deeper, more restorative sleep, the medication aims to reduce the feeling of excessive daytime sleepiness that people with narcolepsy or idiopathic hypersomnia often experience. In this study, the drug is being tested to see if different dosing schedules can provide better control of daytime sleepiness and improve overall daily functioning. The medication is considered an orphan drug, meaning it is approved for a rare condition.

What is already known about the treatment

JZP258 - JZP258 is taken as a 12‑gram oral solution that patients drink, delivering a mix of sodium, calcium, magnesium and potassium oxybate. It is an FDA‑approved orphan drug (sold as Xywav) used to treat narcolepsy and idiopathic hypersomnia, and it has been studied in many clinical trials. The oxybate salts work by increasing activity of the brain chemical GABA at the GABA‑B receptor, which helps deepen sleep at night and reduces excessive daytime sleepiness. It belongs to the class of central nervous system depressants that act as GABA‑B receptor agonists.

Investigated diseases

  • Narcolepsy

    Narcolepsy is a chronic neurological disorder characterized by overwhelming daytime sleepiness and sudden episodes of muscle weakness (cataplexy) in many patients. It typically begins in adolescence or early adulthood and persists throughout life. The condition results from loss of neurons that produce the sleep‑regulating chemical orexin, causing unstable sleep‑wake boundaries. People with narcolepsy often enter rapid eye movement sleep quickly, leading to vivid dreams or hallucinations when falling asleep or waking. Symptoms may fluctuate in intensity, but the core features of sleepiness and cataplexy usually remain present over time.

  • Idiopathic hypersomnia

    Idiopathic hypersomnia is a long‑lasting sleep disorder marked by excessive daytime sleepiness that is not explained by other medical or sleep conditions. It usually starts in childhood or early adulthood and continues without a clear remission period. Affected individuals sleep for long durations at night and still feel unrefreshed, often struggling with prolonged sleep inertia after awakening. The excessive sleepiness can worsen with daily activities and may lead to frequent unplanned naps. While the severity can vary day to day, the underlying tendency toward persistent sleepiness remains stable.

Trial detailsLast updated 21 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-525675-51-00Protocol codeJZP258-304Estimated enrolment85 patientsSponsorJazz Pharmaceuticals Ireland Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.